CONCORD INTERNAL MEDICINE VITAMIN D/CALCIUM/MAGNESIUM PROTOCOL. Revised April 8, 2012

Similar documents
CONCORD INTERNAL MEDICINE CHRONIC KIDNEY DISEASE PROTOCOL. Revised May 30, 2012

Shon E. Meek, M.D., Ph.D. Assistant Professor of Medicine

CONCORD INTERNAL MEDICINE HYPERTENSION PROTOCOL

CONCORD INTERNAL MEDICINE. Peripheral Neuropathy. April 22, 2012

Corporate Presentation January 2013

Chronic Kidney Disease (CKD) and egfr: Decision and Dilemma. Dr Bhavna K Pandya Consultant Nephrologist University Hospital Aintree

RISK FACTORS AND TREATMENT STRATEGIES FOR URINARY STONES Review of NASA s Evidence Reports on Human Health Risks

Clinical biochemistry of calcium and vitamin D

Protocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.

Bone Health in Celiac Disease. Partha S. Sinha MD, PhD October 29 th, 2017

Clinician s Guide to Prevention and Treatment of Osteoporosis

Definition Elevated Adjusted Calcium > 2.6 mmol/l (adjusted for albumin), taken without using a cuff.

HYPERCALCEMIA. Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra hospital, Isfahan university of medical sciences

Bariatric Surgery and Bone Health

Definition Elevated Adjusted Calcium > 2.6 mmol/l (adjusted for albumin), taken without using a cuff.

Parathyroid Disease Scenarios for the Practicing Clinician. Vijaya Chockalingam MD Faculty Endocrinologist Banner University Medical Center- Phoenix

QUICK REFERENCE FOR HEALTHCARE PROVIDERS

CKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow

TRANSLATE CKD Academic Mentoring Intervention Practices. Chester Fox, MD Joseph Vassalotti, MD

Ca, Phos and Vitamin D Metabolism in Pre-Dialysis Patients

Bone strength is proportional to bone mass, measured with DXA. Bone turnover markers indicate the status of bone quality.

Hyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012

Hypercalcemia. Brian Rose, M.D. Bozeman Health June 6, 2018

Special Challenges and Co-Morbidities

Volume and Electrolytes. Fluid and Electrolyte Management. Why 125ml? Question. Normal fluid requirement. Normal losses

CKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College

Management of patients with thyroid cancer scheduled for thyroidectomy at RCHSD

Vitamin D. Mrs Sophie Barnes FRCPath Consultant Clinical Scientist

The Parathyroid Glands

Hellenic Endocrine Society position statement: Clinical management of Vitamin D Deficiency. Spyridon Karras MD, Phd Endocrinologist

Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017

NATIONAL QUALITY FORUM Renal EM Submitted Measures

Dumfries and Galloway. Treatment Protocol for Osteoporosis

Stages of Chronic Kidney Disease (CKD)

Supplementary Online Content

Welcome to the UK Primary Hyperoxaluria family support day

DISCLAIMER DO NOT DISTRIBUTE

Hypocalcemia 6/8/12. Normal value. Physiologic functions. Nephron a functional unit of kidney. Influencing factors in Calcium and Phosphate Balance

Hypercalcemia. Hypercalcemia: When to Worry, When to Treat! Mineral Metabolism : A Short Course

Final Case Study: Renal Disease Due 3/19/14 60 points

Ca, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary

Disclosures. Topics. Staging and GFR. K-DOQI Staging of Chronic Kidney Disease. Definition of Chronic Kidney Disease. Chronic Kidney Disease

Keeping your kidneys young

International Journal of Health Sciences and Research ISSN:

Vitamin D Deficiency. Decreases renal calcium excretion. Increases intestinal absorption Calcium. Increases bone resorption of calcium

Pediatric Nephrology Consult and Referral Guidelines

CKDinform: A PCP s Guide to CKD Detection and Delaying Progression

9/26/2016. The Impact of Dietary Protein on the Musculoskeletal System. Research in dietary protein, musculoskeletal health and calcium economy

Vitamin D: Vitamin D deficiency: 7/6/2010

Case #1. Current Management Strategies in Chronic Kidney Disease. Serum creatinine cont. Pitfalls of Serum Cr

Symptom management: Hypercalcemia

Bone Densitometry Pathway

Persistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019

Vitamin D Hormone Du Jour

Guidelines for the Pharmaceutical Management of Osteoporosis in Adult WA Public Hospitals

Therapeutic golas in the treatment of CKD-MBD

Metabolic Stone Work-Up For Stone Prevention. Dr. Hazem Elmansy, MD, MSC, FRCSC Assistant Professor, NOSM, Urology Department

Vitamin D. Vitamin functioning as hormone. Todd A Fearer, MD FACP

Class Review: Vitamin D Analogs

Identification and qualitative Analysis. of Renal Calculi

Professor Suetonia Palmer

Hypoparathyroidism By John Halpern, DO, FACEP Coauthored by N. Ewen Wang, MD

Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol

Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital

Vitamin D Deficiency. Micol Rothman, MD Assistant Professor of Medicine Clinical Director Metabolic Bone Program University of CO-Denver

Chronic Kidney Disease

Optimizing Vitamin D Treatment in HIV/AIDS: An RCT. The FDA and Me

Sachin Soni DNB Pediatrics

76 year-old female presents with muscle cramps. Jess Hwang 12/6/12

Clinical Study Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing Hormone Analog

Dumfries and Galloway. Treatment Protocol for Osteoporosis

Hyperparathyroidism. There is however another more potent method to achieve the lowering of PTH in a more natural way.

Identifying and Managing Chronic Kidney Disease: A Practical Approach

Key words: Vitamin D analogues, alfacalcidol, calcitriol, secondary hyperparathyroidism, renal dialysis

Management of the post-bariatric surgery patient: She s in my office. Now what do I do?

Dietary Management of Nephrolithiasis. Sarah Yttri, NP Duke University Duke Comprehensive Kidney Stone Center

A Rare Cause of Renal Stone Formation in Two Siblings. Chris Stockdale

PRIMARY HYPERPARATHYROIDISM

Chronic Kidney Disease The 6 Pillars. Dr. Tiina Podymow Associate Professor Division of Nephrology McGill University Health Centre

2.0 Synopsis. Paricalcitol Capsules M Clinical Study Report R&D/15/0380. (For National Authority Use Only)

CKD-MBD CKD mineral bone disorder

The most current assessment of this problem can be found in the Apex note dated

NATIONAL KIDNEY MONTH

David Bruyette, DVM, DACVIM

>4000 mg/dl (=20000/(500/100)) >615 mmol/l (=20000/(65*0.5))

Sensipar. Sensipar (cinacalcet) Description

Disclosure and Conflicts of Interest Steven T Harris MD Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis

Osteoporosis and Chronic Kidney Disease: Diagnosis and Treatment Recommendations

Primary Care Physicians and Clinicians. XXX on behalf of the Upper Midwest Fistula First Coalition. Chronic Kidney Disease (CKD) Resources

Disclosure. Topic Outline. Calcium, Vitamin D, PTH Disorders. PTH/Calcium-Normal Physiology. I have nothing to disclose

Renal Remission Clinic Protocols

Secondary Hyperparathyroidism: Where are we now?

Kristen M. Nebel, DO PENN/ LGHP Geriatrics. Temple Family Medicine Review

The future is here. It s just not widely distributed yet. William Gibson

Medical Approach to Nephrolithiasis. Seth Goldberg, MD September 15, 2017 ACP Meeting

UPDATES ON PRIMARY HYPERPARATHYROIDISM. Natalie E. Cusano, MD, MS Director, Bone Metabolism Program Lenox Hill Hospital New York, NY

Diagnosis: Allergies with reaction type:

MEDICAL POLICY EFFECTIVE DATE: 08/21/14 REVISED DATE: 04/16/15, 06/16/16, 07/20/17 SUBJECT: SCREENING FOR VITAMIN D DEFICIENCY

VA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERENCE CARDS Chronic Kidney Disease

Case Studies: Renal and Urologic Impairments Workshop

Transcription:

CONCORD INTERNAL MEDICINE VITAMIN D/CALCIUM/MAGNESIUM PROTOCOL Douglas G. Kelling, Jr., ND C. Gismondi-Eagan, MD, FACP George C. Monroe, III, MD Revised April 8, 2012 The information contained in this protocol should never be used as a substitute for clinical judgment. The clinician and the patient need to develop an individual treatment plan that is tailored to the specific needs and circumstances of the patient.

Vitamin D/Calcium/Magnesium Protocol Table of Contents Page(s) 25 Hydroxyvitamin D Levels 1-7 1,25-Dihydroxyvitamin D Levels 8-9 Urinary Calcium/Creatinine Ratio 10 Magnesium Tolerance Test 11 Treatment with Magnesium Oxide 12 Malabsorption Workup 13

Page 1 VITAMIN D/CALCIUM/MAGNESIUM PROTOCOL IN PATIENTS WITH AN ABNORMAL DXA SCAN, NON-TRAUMATIC FRACTURE OR LOW SERUM CALCIUM MEASURE 25 HYDROXYVITAMIN D LEVEL AND ipth LEVEL (Draw 8am to 10am) 25-Hydroxyvitamin D < 20 25-Hydroxyvitamin D > 20 and < 30 25-Hydroxyvitamin D > 30 ipth > 65 if GFR > 60 ipth > 70 if GFR 30-59 ipth > 110 if GFR 15-29 ipth > 300 if GFR < 15 or dialysis ipth < 65 if GFR > 60 ipth < 70 if GFR 30-59 ipth < 110 if GFR 15-29 ipth < 300 if GFR < 15 or dialysis ipth > 65 if GFR > 60 ipth > 70 if GFR 30-59 ipth > 110 if GFR 15-29 ipth > 300 if GFR < 15 or dialysis ipth < 65 if GFR > 60 ipth < 70 if GFR 30-59 ipth < 110 if GFR 15-29 ipth < 300 if GFR < 15 or dialysis Page 6 Page 2 Page 3 Page 4 Page 5

Page 2 25 Hydroxyvitamin D Level < 20 ipth > 65 if GFR > 60 ipth > 70 if GFR 30-59 ipth > 110 if GFR 15-29 ipth > 300 if GFR < 15 or dialysis Elevated Serum Calcium Endocrinologist to evaluate for Primary Hyperparathyroidism Normal Serum Calcium or Normal serum corrected calcium (cca) Low and low cca *Elemental Calcium 500 mg/bid daily Vitamin D 50,000 IU weekly x 8 weeks then continue monthly In 12 weeks, Remeasure: Serum cca if clinically indicated 25-Hydroxyvitamin D ipth (Draw 8am to 10am) Page 7 *Consider using calcium citrate if the patient has a history of kidney stones and patient s creatinine clearance is >60, otherwise use Calcium carbonate. If patient has a history of kidney stones measure urinary calcium/creatinine ratio before and 12 wks after starting calcium supplementation.

Page 3 25 Hydroxyvitamin D Level < 20 ipth < 65 if GFR > 60 ipth < 70 if GFR 30-59 ipth < 110 if GFR 15-29 ipth < 300 if GFR < 15 or dialysis Elevated First measurements of serum Calcium, 25 Hydroxyvitamin D and ipth levels? Normal or normal serum corrected calcium (cca) Low And cca *Elemental Calcium 500 mg/bid daily No Remeasure Serum Calcium, 25 Hydroxyvitamin D and intact PTH levels Page 1 Reevaluate Patient Vitamin D 50,000 IU weekly x 8 weeks In 12 weeks, Remeasure: Serum cca if clinically indicated 25-Hydroxyvitamin D ipth (Draw 8am to 10am) Magnesium Tolerance Test Page 11 Page 7 *Consider using calcium citrate if the patient has a history of kidney stones and patient s creatinine clearance is >60, otherwise use calcium carbonate. If patient has a history of kidney stones measure urinary calcium/creatinine ratio before and 12 wks after starting calcium supplementation.

Page 4 25 Hydroxyvitamin D Level > 20 AND < 30 ipth > 65 if GFR > 60 ipth > 70 if GFR 30-59 ipth > 110 if GFR 15-29 ipth > 300 if GFR < 15 or dialysis Elevated serum Calcium Endocrinologist to evaluate for Primary Hyperparathyroidism Normal Or normal serum corrected calcium (cca) *Elemental Calcium 500 mg/bid daily Vitamin D 50,000 IU weekly x 4 weeks Low and low cca *Elemental Calcium 500 mg/tid daily Vitamin D 50,000 IU weekly x 4 weeks Normal Repeat High In 12 weeks, Remeasure: Serum cca if clinically indicated 25-Hydroxyvitamin D ipth (Draw 8am to 10am) 8am Spot urine for NTx Vitamin D 50,000 IU Weekly x 2 weeks Endocrinologist to evaluate for Primary Hyperparathyroidism Stop Calcium, Multivitamin and Vitamin D Page 7 *Consider using calcium citrate if the patient has a history of kidney stones and patient s creatinine clearance is >60, otherwise use Calcium carbonate. If patient has a history of kidney stones measure urinary calcium/creatinine ratio before and 12 wks after starting calcium supplementation.

Page 5 25-Hydroxyvitamin D Level > 20 AND < 30 ipth < 65 if GFR > 60 ipth < 70 if GFR 30-59 ipth < 110 if GFR 15-29 ipth < 300 if GFR < 15 or dialysis Elevated serum Calcium Normal or normal serum corrected calcium (cca) Low and low cca First measurements of serum Calcium, 25 Hydroxyvitamin D and ipth levels? *Elemental Calcium 500 mg/bid daily *Elemental Calcium 500 mg/tid daily No Reevaluate patient Vitamin D 50,000 IU weekly x 4 weeks Magnesium Tolerance Test Page 11 Remeasure Serum Calcium, 25 Hydroxyvitamin D and ipth levels Page 1 In 12 weeks, Remeasure: Serum cca of clinically indicated 25-Hydroxyvitamin D ipth (Draw 8am to 10am) 8 am Spot urine for NTx Page 7 *Consider using calcium citrate if the patient has a history of kidney stones and patient s creatinine clearance is >60, otherwise use calcium carbonate. If patient has a history of kidney stones measure urinary calcium/creatinine ratio before and 12 wks after starting calcium supplementation.

Page 6 25 Hydroxyvitamin D Level > 30 Yes Is calculated GFR is > 60? No See Chronic Kidney Disease (CKD) protocol Low, low cca, and High ipth Level Elevated and low ipth Level Normal or elevated Serum Calcium and High ipth Level Normal serum calcium and Normal ipth Measure 1,25 Dihydroxyvitamin D Level 1,25-Dihydroxy- Vitamin D Level < 20 1,25-Dihydroxy- Vitamin D Level > 20 Consider granulomalous disease, lymphoma, or TB Endocrinologist to evaluate for Primary Hyperparathyroidism *Elemental Calcium 500 mg BID with food PLUS Vitamin D 50,000 units twice a month (suggest 1 st & 15 th each month) See Page 8 See Page 9 Low or normal serum calcium and Low ipth Elevated and Low ipth level 25 hydroxyvitamin D level yearly First measurements of serum calcium, 25 Hydroxyvitamin D and ipth levels? Measure PTH-like peptide See Page 1 *Consider using calcium citrate if the patient has a history of kidney stones, and patient s creatinine clearance is >60, otherwise use calcium carbonate. No Remeasure serum Calcium, 25 Hydroxyvitamin D and ipth levels Reevaluate patient Elevated PTHlike peptide Evaluate for metastatic cancer Normal PTH-like peptide Measure urinary Calcium/Creatinine ratio If patient has a history of kidney stones measure urinary calcium/creatinine ratio before and 12 wks after starting calcium supplementation. See Page 1 Re-evaluate patient

Page 7 25 Hydroxyvitamin D Level Remeasured after treatment with high dose Vitamin D 25-Hydroxyvitamin D < 20 25-Hydroxyvitamin D >20 < 30 25-Hydroxyvitamin D > 30 Malabsorption workup Page 13 Vitamin D 50,000 IU weekly x 4 weeks page 6 Urine dipstick for protein Remeasure 25-Hydroxyvitamin D Level Negative for protein Positive for protein 25-Hydroxyvitamin D <30 25-Hydroxyvitamin D > 30 No further work up 24 hour urine for protein and creatinine >4 grams of protein in 24 hr urine Malabsorption Workup Page 13 Nephrologist for evaluation of nephrotic syndrome Measure Vitamin D- binding protein

Page 8 1,25-Dihydroxyvitamin D Level Low 1,25-Dihydroxyvitamin D (Rocaltrol) 0.25 mcg po BID x 8 weeks Re-measure 1,25-Dihydroxyvitamin D Level 1,25-Dihydroxyvitamin D Level low 1,25-Dihydroxyvitamin D Level normal 1,25-Dihydroxyvitamin D Level high 1,25-Dihydroxyvitamin D (Rocaltrol) 0.25 mcg po BID x 4 weeks Re-measure 1,25-Dihydroxy- Vitamin D Level ipth level within normal limits Measure PTH Level (Draw 8am to 10am) Elevated ipth Level Stop Rocaltrol Physician to re-evaluate patient 1,25-Dihydroxyvitamin D Level low 1,25-Dihydroxyvitamin D Level normal Measure serum Calcium and cca if clinically indicated Malabsorption work up Page 13 and cca within normal limits Low Serum Calcium and low cca if measured Low serum calcium and low cca if measured Normal or elevated serum calcium or normal or elevated cca No further work up Page 9 Endocrinologist

Page 9 Measure urinary Calcium/Creatinine Ratio < 0.2 mg for women < 0.25 mg for men >0.2 mg to 0.25 mg for women >.25 mg to 0.3 mg for men > 0.25 mg for women > 0.3 mg for men Make sure patient taking total of 1500 mg of elemental Calcium a day Magnesium Tolerance Test (Valid only if patient has normal renal functioncalculated GFR >60 Page 11 Magnesium Retention >25% Magnesium Retention < 25% In 3 months remeasure urinary Calcium/Creatinine Ratio Magnesium Deficiency Treat with Magnesium Oxide Page 11 Treat for Idiopathic Hypercalciuria Magnesium Tolerance Test - Page 10 Magnesium Retention >25% Magnesium Retention <25% Magnesium Deficiency Treat with Magnesium oxide Page 11 Re-evaluate Patient

Page 10 MAGNESIUM TOLERANCE TEST Valid only if patient has normal renal function (calculated GFR > 60) Collect 24-hour urine for magnesium and creatinine. (Computer code MAGUPR) Once the initial 24 hour urine collection is completed, infuse 0.2 meq (2.4mg) elemental magnesium per Kg lean body weight in 50ml 5% dextrose over a 4 hour period. At the start of the magnesium infusion, begin another 24 hour urine collection for magnesium and creatinine (Computer Code MAGUPO) Date Time Physician Signature Patient Sticker NORTHEAST MEDICAL CENTER STANDING ORDERS DR. KELLING MAGNESIUM TOLERANCE TEST RESULTS OF MAGNESIUM TOLERANCE TEST Magnesium Retention <25% Magnesium Retention >25% No evidence magnesium deficiency Magnesium Deficiency Treat with Magnesium oxide See Page 11 Re-evaluate Patient

Page 11 Treatment with Magnesium Oxide Creatinine Clearance > 30 Magnesium Oxide 400mg BID Patient intolerant of dose No Yes Measure serum magnesium level 1 and 3 weeks after beginning Magnesium Oxide Decrease dose to Magnesium Oxide 400mg Low Serum Magnesium Normal Serum Magnesium High Serum Magnesium Patient intolerant of dose No Yes Increase Magnesium Oxide by 400mg a day Continue same dose magnesium oxide Stop Magnesium Oxide and re-evaluate patient Re-evaluate patient Measure Serum Magnesium level 1 and 3 weeks after increasing the dose of Magnesium Oxide Repeat serum magnesium level as clinically indicated Patient intolerant of dose No Yes Re-evaluate patient Low Serum Magnesium Normal Serum Magnesium High Serum Magnesium Re-evaluate patient Continue same dose magnesium oxide Stop Magnesium Oxide and re-evaluate patient Repeat serum magnesium level as clinically indicated

Page 12 Malabsorption Workup Measure: D-xylose test Serum IgA level IgA antitissue transglutaminase antibody Osteocalcin (if not already measured) Antibodies positive and D-xylose test abnormal Antibodies negative and D-xylose test abnormal Antibodies negative and D-xylose test normal GI for further evaluation for sprue GI for further evaluation of causes of mucosal malabsorption other than sprue GI to evaluate for pancreatis insufficiency